APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nuclear Medicine & Radiopharmaceuticals

Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positronemitting radiopharmaceuticals.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positronemitting radiopharmaceuticals.

Selected research

Market Outlook & Growth Opportunities

Global Nuclear Medicine & Radiopharmaceuticals Market Outlook and Growth Opportunities 2026

Report ID 17401806041 January 2026198 pages

Choose your research edition.

Industry ResearchNuclear Medicine & Radiopharmaceuticals Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Nuclear Medicine & Radiopharmaceuticals Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Nuclear Medicine & Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nuclear Medicine & Radiopharmaceuticals Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Nuclear Medicine & Radiopharmaceuticals Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Radiopharmaceuticals (also known as radioactive drugs) are drugs that contain radionuclides that emit radiation. The distribution of the radiopharmaceutical within the body is determined by the physiochemical properties of the drug, the stability of the radiolabel, the purity of the radiopharmaceutical preparation, the pathophysiologic state of the patient, and the presence or absence of interfering drugs. Dynamic and static images of the distribution of the radiopharmaceutical within the body can be obtained using a g-camera or another suitable instrument appropriate for the radiopharmaceutical being imaged—for example, positronemitting radiopharmaceuticals.

The major players in Chian Nuclear Medicine & Radiopharmaceuticals market include China Isotope & Radiation, Shanghai Atom Kexing, Advanced Molecular-imaging Solution, etc. Beijing and Chengdu are main markets, they occupy about 65% of the whole market. Diagnostic is the main type, with a share about 80%. Cardiology is the main application, which holds a share about 40%.

This report provides an overview of the global Nuclear Medicine & Radiopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Nuclear Medicine & Radiopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nuclear Medicine & Radiopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nuclear Medicine & Radiopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.

Nuclear Medicine & Radiopharmaceuticals Segment by Company

China Isotope & Radiation

Dongcheng

Jaco

Ciaeriar

Advanced Molecular-imaging Solution

Shanghai Atom Kexing

Nuclear Medicine & Radiopharmaceuticals Segment by Type

Diagnostic

Therapeutic

Nuclear Medicine & Radiopharmaceuticals Segment by Application

Oncology

Thyroid

Cardiology

Others

Nuclear Medicine & Radiopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nuclear Medicine & Radiopharmaceuticals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nuclear Medicine & Radiopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nuclear Medicine & Radiopharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze Nuclear Medicine & Radiopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nuclear Medicine & Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nuclear Medicine & Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nuclear Medicine & Radiopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nuclear Medicine & Radiopharmaceuticals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nuclear Medicine & Radiopharmaceuticals industry.

Chapter 3: Detailed analysis of Nuclear Medicine & Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nuclear Medicine & Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nuclear Medicine & Radiopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nuclear Medicine & Radiopharmaceuticals Industry Trends Table 2. Nuclear Medicine & Radiopharmaceuticals Industry Drivers Table 3. Nuclear Medicine & Radiopharmaceuticals Industry Opportunities and Challenges Table 4. Nuclear Medicine & Radiopharmaceuticals Industry Restraints Table 5. Global Nuclear Medicine & Radiopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nuclear Medicine & Radiopharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Company (2021-2026) Table 9. Global Nuclear Medicine & Radiopharmaceuticals Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Nuclear Medicine & Radiopharmaceuticals Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nuclear Medicine & Radiopharmaceuticals Key Company Manufacturing Base & Headquarters Table 12. Global Nuclear Medicine & Radiopharmaceuticals Company, Product Type & Application Table 13. Global Nuclear Medicine & Radiopharmaceuticals Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nuclear Medicine & Radiopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Diagnostic Table 18. Significant Companies of Therapeutic Table 19. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Type (2021-2026) Table 23. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Type (2027-2032) Table 24. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type (2021-2026) Table 28. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Oncology Table 30. Significant Companies of Thyroid Table 31. Significant Companies of Cardiology Table 32. Significant Companies of Others Table 33. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Application (2021-2026) Table 37. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Application (2027-2032) Table 38. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application (2021-2026) Table 42. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application (2027-2032) Table 43. Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2021-2026) & (K Units) Table 45. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region (2021-2026) Table 46. Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2027-2032) & (K Units) Table 47. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region (2027-2032) Table 48. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Region (2021-2026) Table 51. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Region (2027-2032) Table 53. Global Nuclear Medicine & Radiopharmaceuticals Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Nuclear Medicine & Radiopharmaceuticals Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Nuclear Medicine & Radiopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021-2026) & (K Units) Table 58. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Country (2021-2026) Table 59. Global Nuclear Medicine & Radiopharmaceuticals Sales by Country (2027-2032) & (K Units) Table 60. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Country (2027-2032) Table 61. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Market Share by Country (2021-2026) Table 63. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Market Share by Country (2027-2032) Table 65. China Isotope & Radiation Company Information Table 66. China Isotope & Radiation Business Overview Table 67. China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product Portfolio Table 69. China Isotope & Radiation Recent Development Table 70. Dongcheng Company Information Table 71. Dongcheng Business Overview Table 72. Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Dongcheng Nuclear Medicine & Radiopharmaceuticals Product Portfolio Table 74. Dongcheng Recent Development Table 75. Jaco Company Information Table 76. Jaco Business Overview Table 77. Jaco Nuclear Medicine & Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Jaco Nuclear Medicine & Radiopharmaceuticals Product Portfolio Table 79. Jaco Recent Development Table 80. Ciaeriar Company Information Table 81. Ciaeriar Business Overview Table 82. Ciaeriar Nuclear Medicine & Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Ciaeriar Nuclear Medicine & Radiopharmaceuticals Product Portfolio Table 84. Ciaeriar Recent Development Table 85. Advanced Molecular-imaging Solution Company Information Table 86. Advanced Molecular-imaging Solution Business Overview Table 87. Advanced Molecular-imaging Solution Nuclear Medicine & Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Advanced Molecular-imaging Solution Nuclear Medicine & Radiopharmaceuticals Product Portfolio Table 89. Advanced Molecular-imaging Solution Recent Development Table 90. Shanghai Atom Kexing Company Information Table 91. Shanghai Atom Kexing Business Overview Table 92. Shanghai Atom Kexing Nuclear Medicine & Radiopharmaceuticals Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Shanghai Atom Kexing Nuclear Medicine & Radiopharmaceuticals Product Portfolio Table 94. Shanghai Atom Kexing Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Nuclear Medicine & Radiopharmaceuticals Distributors List Table 98. Nuclear Medicine & Radiopharmaceuticals Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Nuclear Medicine & Radiopharmaceuticals Product Image Figure 2. Global Nuclear Medicine & Radiopharmaceuticals Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nuclear Medicine & Radiopharmaceuticals Sales (2021-2032) & (K Units) Figure 5. Global Nuclear Medicine & Radiopharmaceuticals Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Nuclear Medicine & Radiopharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Diagnostic Image Figure 10. Therapeutic Image Figure 11. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Type (2021-2032) Figure 14. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type (2021-2032) Figure 17. Oncology Image Figure 18. Thyroid Image Figure 19. Cardiology Image Figure 20. Others Image Figure 21. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Application (2021-2032) Figure 24. Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application (2021-2032) Figure 27. Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Nuclear Medicine & Radiopharmaceuticals Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 32. North America Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 38. South America Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Nuclear Medicine & Radiopharmaceuticals Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Nuclear Medicine & Radiopharmaceuticals Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic
  • Therapeutic
Applications
  • Oncology
  • Thyroid
  • Cardiology
  • Others
Companies covered
  • China Isotope & Radiation
  • Dongcheng
  • Jaco
  • Ciaeriar
  • Advanced Molecular-imaging Solution
  • Shanghai Atom Kexing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032)
  4. 1.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume (2021-2032)
  5. 1.2.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nuclear Medicine & Radiopharmaceuticals Market Dynamics
  1. 2.1 Nuclear Medicine & Radiopharmaceuticals Industry Trends
  2. 2.2 Nuclear Medicine & Radiopharmaceuticals Industry Drivers
  3. 2.3 Nuclear Medicine & Radiopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 Nuclear Medicine & Radiopharmaceuticals Industry Restraints
3 Nuclear Medicine & Radiopharmaceuticals Market by Company
  1. 3.1 Global Nuclear Medicine & Radiopharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global Nuclear Medicine & Radiopharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Company (2021-2026)
  4. 3.4 Global Nuclear Medicine & Radiopharmaceuticals Average Price by Company (2021-2026)
  5. 3.5 Global Nuclear Medicine & Radiopharmaceuticals Company Ranking (2024-2026)
  6. 3.6 Global Nuclear Medicine & Radiopharmaceuticals Company Manufacturing Base and Headquarters
  7. 3.7 Global Nuclear Medicine & Radiopharmaceuticals Company Product Type and Application
  8. 3.8 Global Nuclear Medicine & Radiopharmaceuticals Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nuclear Medicine & Radiopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nuclear Medicine & Radiopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nuclear Medicine & Radiopharmaceuticals Market by Type
  1. 4.1 Nuclear Medicine & Radiopharmaceuticals Type Introduction
  2. 4.1.1 Diagnostic
  3. 4.1.2 Therapeutic
  4. 4.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Type
  5. 4.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Type
  9. 4.3.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Type (2021-2032)
  11. 4.3.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type (2021-2032)
5 Nuclear Medicine & Radiopharmaceuticals Market by Application
  1. 5.1 Nuclear Medicine & Radiopharmaceuticals Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Thyroid
  4. 5.1.3 Cardiology
  5. 5.1.4 Others
  6. 5.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Application
  7. 5.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Application
  11. 5.3.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Application (2021-2032)
  13. 5.3.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application (2021-2032)
6 Nuclear Medicine & Radiopharmaceuticals Regional Sales and Value Analysis
  1. 6.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2021-2032)
  3. 6.2.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region: 2021-2026
  4. 6.2.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Region (2027-2032)
  5. 6.3 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Region (2027-2032)
  9. 6.5 Global Nuclear Medicine & Radiopharmaceuticals Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032)
  12. 6.6.2 North America Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032)
  15. 6.7.2 Europe Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032)
  21. 6.9.2 South America Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nuclear Medicine & Radiopharmaceuticals Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 Nuclear Medicine & Radiopharmaceuticals Country-level Sales and Value Analysis
  1. 7.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021-2032)
  4. 7.3.1 Global Nuclear Medicine & Radiopharmaceuticals Sales by Country (2021-2026)
  5. 7.3.2 Global Nuclear Medicine & Radiopharmaceuticals Sales by Country (2027-2032)
  6. 7.4 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nuclear Medicine & Radiopharmaceuticals Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nuclear Medicine & Radiopharmaceuticals Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nuclear Medicine & Radiopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China Isotope & Radiation
  2. 8.1.1 China Isotope & Radiation Company Information
  3. 8.1.2 China Isotope & Radiation Business Overview
  4. 8.1.3 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 China Isotope & Radiation Nuclear Medicine & Radiopharmaceuticals Product Portfolio
  6. 8.1.5 China Isotope & Radiation Recent Developments
  7. 8.2 Dongcheng
  8. 8.2.1 Dongcheng Company Information
  9. 8.2.2 Dongcheng Business Overview
  10. 8.2.3 Dongcheng Nuclear Medicine & Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Dongcheng Nuclear Medicine & Radiopharmaceuticals Product Portfolio
  12. 8.2.5 Dongcheng Recent Developments
  13. 8.3 Jaco
  14. 8.3.1 Jaco Company Information
  15. 8.3.2 Jaco Business Overview
  16. 8.3.3 Jaco Nuclear Medicine & Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jaco Nuclear Medicine & Radiopharmaceuticals Product Portfolio
  18. 8.3.5 Jaco Recent Developments
  19. 8.4 Ciaeriar
  20. 8.4.1 Ciaeriar Company Information
  21. 8.4.2 Ciaeriar Business Overview
  22. 8.4.3 Ciaeriar Nuclear Medicine & Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ciaeriar Nuclear Medicine & Radiopharmaceuticals Product Portfolio
  24. 8.4.5 Ciaeriar Recent Developments
  25. 8.5 Advanced Molecular-imaging Solution
  26. 8.5.1 Advanced Molecular-imaging Solution Company Information
  27. 8.5.2 Advanced Molecular-imaging Solution Business Overview
  28. 8.5.3 Advanced Molecular-imaging Solution Nuclear Medicine & Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Advanced Molecular-imaging Solution Nuclear Medicine & Radiopharmaceuticals Product Portfolio
  30. 8.5.5 Advanced Molecular-imaging Solution Recent Developments
  31. 8.6 Shanghai Atom Kexing
  32. 8.6.1 Shanghai Atom Kexing Company Information
  33. 8.6.2 Shanghai Atom Kexing Business Overview
  34. 8.6.3 Shanghai Atom Kexing Nuclear Medicine & Radiopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Atom Kexing Nuclear Medicine & Radiopharmaceuticals Product Portfolio
  36. 8.6.5 Shanghai Atom Kexing Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nuclear Medicine & Radiopharmaceuticals Value Chain Analysis
  2. 9.1.1 Nuclear Medicine & Radiopharmaceuticals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nuclear Medicine & Radiopharmaceuticals Sales Mode & Process
  6. 9.2 Nuclear Medicine & Radiopharmaceuticals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nuclear Medicine & Radiopharmaceuticals Distributors
  9. 9.2.3 Nuclear Medicine & Radiopharmaceuticals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst